Hereditary transthyretin-mediated amyloidosis is a rare, progressive and potentially life- limiting multisystem disease, affecting every aspect of a patient’s life. This online international Delphi survey aimed to evolve clinical−patient-led practical guidance, to inspire and encourage a holistic approach to care that is managed in specialist settings by multidisciplinary teams [...]
PBAC has recommended PBS listing of Vyndamax®(tafamidis) 61mg for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) with NYHA Class I-II heart failure. The latest Pharmaceutical Benefits Advisory Committee (PBAC) Meeting was held in July and it recommended the Public Benefit Scheme (PBS) listing of Vyndamax (tafamidis) 61 mg for patients [...]
Vaccination is vital to help control COVID-19 and keep you and the community well. If we in Australia with the rest of the world are going to control COVID-19 also known as the Coronavirus and we want the Australian state borders to remain open, it is extremely important [...]
Authors David Adams Yukio Ando João Melo Beirão Teresa Coelho Morie A. Gertz Julian D. Gillmore Philip N. Hawkins Isabelle Lousada Ole B. Suhr Giampaolo Merlini Abstract Amyloid transthyretin (ATTR) amyloidosis with polyneuropathy (PN) is a progressive, debilitating, systemic disease wherein transthyretin protein misfolds to form amyloid, which is deposited in the endoneurium. ATTR amyloidosis with PN is the most serious hereditary polyneuropathy [...]
Reports from the 2nd European meeting for ATTR amyloidosis for doctors and patients from the NZ ATTR Amyloidosis Patients Association and the Australian ATTR Amyloidosis Alliance representative. This very successful fourday conference was held at the beginning of September in Berlin. Amongst the delegates were Jaime and Aubrey Christmas who [...]
The International Myeloma Workshop was held in Boston, USA from 12th-15th September 2019. This is a conference attended by >3000 medical professionals every 2 years, where world leaders in the treatment of myeloma and associated disease - such as systemic AL amyloidosis - present and discuss data regarding new [...]
